Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (1034)

« Back to Publications

Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN.

Oppenheimer J. et al, (2026), Advances in therapy, 43, 729 - 749

Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthma.

Pavord ID. et al, (2026), The Journal of allergy and clinical immunology, 157, 363 - 373

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE).

Chupp G. et al, (2026), American journal of respiratory and critical care medicine

Shaping the Future of Respiratory Care: A Look Into the Next Decade and Strategic Recommendations by European Forum for Research and Education in Allergy and Airways Diseases.

Bertels X. et al, (2026), Chest

Normal FEV1 without Reversibility in Asthma Trials: A Placebo Patient-Level Meta-Analysis

Couillard S. et al, (2025), American Journal of Respiratory and Critical Care Medicine, 211, 2396 - 2399

Misconceptions of Traits to Predict Response to Inhaled Corticosteroid and Bronchodilator Therapies in Asthma: A Narrative Review.

Brusselle G. et al, (2025), Pulmonary therapy

Acceptability and feasibility of biomarkers of airway eosinophilic inflammation for the management of preschool wheeze: a qualitative study.

Perikleous A. et al, (2025), Archives of disease in childhood

Understanding the relationship between eosinophils and chronic obstructive pulmonary disease. A new dawn?

Tiedeman C. and Pavord I., (2025), Expert review of respiratory medicine, 1 - 9

Biological Therapies in Chronic Obstructive Pulmonary Disease: New Directions in Personalised Respiratory Medicine

Mappin-Kasirer B. and Pavord ID., (2025), BioDrugs, 39, 827 - 839

Fractional exhaled nitric oxide and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Rα therapy: a prospective observational study

Howell I. et al, (2025), European Respiratory Journal, 66, 2501229 - 2501229

The Risk–Benefit Balance of Oral Corticosteroid Treatment for Asthma Attacks: A Discrete Choice Experiment of Patients and Healthcare Professionals in the UK and New Zealand

Howell I. et al, (2025), Respirology, 30, 1035 - 1045

An anti-inflammatory reliever algorithm approach to asthma management in adults: an open-label, single-arm trial.

Bruce P. et al, (2025), EClinicalMedicine, 89

Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage.

Porsbjerg C. et al, (2025), The Lancet. Respiratory medicine, 13, 1026 - 1040

Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma.

McDowell PJ. et al, (2025), The Journal of allergy and clinical immunology, 156, 911 - 922

Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?

Davies TJ. and Pavord ID., (2025), The European respiratory journal, 66

Load More

1
2
3
4
5
6
7
...
»